Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Nykode Therapeutics - Grant of Share Options

Nykode Therapeutics
Oslo, Norway, July 9, 2025 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that a total of 12,795,000
share options have been granted to employees of Nykode Therapeutics ASA under
the company's share option scheme, of which 8,250,000 share options have been
granted to primary insiders. The share options will have a strike price of NOK
7.00 per share, have a five-year term and will vest equally over a four-year
vesting period.

Concurrently with the grant, a total of 7,376,973 previously granted share
options, of which 6,075,906 relate to primary insiders, will be cancelled. The
cancelled share options represent substantially all outstanding options in
Nykode Therapeutics ASA prior to the new grant.

Please see further details in attached document.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.